Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus PERINDOPRIL ERBUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus PERINDOPRIL ERBUMINE.
ACEON vs PERINDOPRIL ERBUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Perindopril is a prodrug that is hydrolyzed to perindoprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and catecholamine release, leading to decreased blood pressure.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
2.5–10 mg orally once daily; initial dose 2.5 mg for hypertension, 4 mg for stable coronary artery disease; titrate based on response.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
The terminal elimination half-life of perindopril is 1.5–3 hours, but for the active metabolite perindoprilat it is 30–120 hours, due to slow dissociation from tissue ACE. This long half-life supports once-daily dosing for 24-hour blood pressure control.
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Perindopril is extensively metabolized to perindoprilat. Approximately 75% of an oral dose is excreted in urine (as perindoprilat and metabolites) and 25% in feces (mainly as perindoprilat). Less than 5% is excreted unchanged in urine. Biliary excretion is minimal.
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor